These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32368520)

  • 1. Pre-treatment lost to follow-up tuberculosis patients, Chongwe, Zambia, 2017: a retrospective cohort study.
    Chilembo M; Oguri S; Matsuoka Y; Ota M; Musiankuni P; Kabungo J
    Public Health Action; 2020 Mar; 10(1):21-26. PubMed ID: 32368520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes of pre-treatment loss to follow-up in patients with TB.
    Daka S; Matsuoka Y; Ota M; Hirao S; Phiri A
    Public Health Action; 2022 Dec; 12(4):148-152. PubMed ID: 36561903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiologically Confirmed Tuberculosis: Factors Associated with Pre-Treatment Loss to Follow-Up, and Time to Treatment Initiation.
    Mwansa-Kambafwile J; Maitshotlo B; Black A
    PLoS One; 2017; 12(1):e0168659. PubMed ID: 28068347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear.
    Zimba O; Tamuhla T; Basotli J; Letsibogo G; Pals S; Mathebula U; Mathoma A; Serumola C; Ramogale K; Boyd R; Tran T; Finlay A; Auld A; Date A; Alexander H; Chihota V; Agizew T
    Pan Afr Med J; 2019; 33():110. PubMed ID: 31489088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
    Raizada N; Sachdeva KS; Nair SA; Kulsange S; Gupta RS; Thakur R; Parmar M; Gray C; Ramachandran R; Vadera B; Ekka S; Dhawan S; Babre A; Ghedia M; Alavadi U; Dewan P; Khetrapal M; Khanna A; Boehme C; Paramsivan CN
    PLoS One; 2014; 9(8):e105346. PubMed ID: 25140877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.
    Mavenyengwa RT; Shaduka E; Maposa I
    Infect Dis Poverty; 2017 Jan; 6(1):13. PubMed ID: 28086955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.
    Peter J; Theron G; Chanda D; Clowes P; Rachow A; Lesosky M; Hoelscher M; Mwaba P; Pym A; Dheda K;
    BMC Infect Dis; 2015 Jul; 15():262. PubMed ID: 26156025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.
    Balcha TT; Sturegård E; Winqvist N; Skogmar S; Reepalu A; Jemal ZH; Tibesso G; Schön T; Björkman P
    PLoS One; 2014; 9(1):e85478. PubMed ID: 24465572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial.
    Agizew T; Chihota V; Nyirenda S; Tedla Z; Auld AF; Mathebula U; Mathoma A; Boyd R; Date A; Pals SL; Lekone P; Finlay A
    BMC Infect Dis; 2019 Dec; 19(1):1058. PubMed ID: 31842773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and CT characteristics of Xpert MTB/RIF-negative pulmonary tuberculosis.
    Lee HN; Kim JI; Kim YH
    PLoS One; 2021; 16(5):e0250616. PubMed ID: 33939723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How well does the process of screening and diagnosis work for HIV-infected persons identified with presumptive tuberculosis who are attending HIV care and treatment clinics in Harare city, Zimbabwe?
    Takarinda KC; Choto R; Sandy C; Apollo T; Duri C; Dube F; Mpofu A; Timire C; Mugurungi O; Makaza V; Tapera R; Harries AD
    Trans R Soc Trop Med Hyg; 2018 Oct; 112(10):450-457. PubMed ID: 30032237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending 'Contact Tracing' into the Community within a 50-Metre Radius of an Index Tuberculosis Patient Using Xpert MTB/RIF in Urban, Pakistan: Did It Increase Case Detection?
    Fatima R; Qadeer E; Yaqoob A; Haq MU; Majumdar SS; Shewade HD; Stevens R; Creswell J; Mahmood N; Kumar AM
    PLoS One; 2016; 11(11):e0165813. PubMed ID: 27898665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.
    Raizada N; Sachdeva KS; Swaminathan S; Kulsange S; Khaparde SD; Nair SA; Khanna A; Chopra KK; Hanif M; Sethi GR; Umadevi KR; Keshav Chander G; Saha B; Shah A; Parmar M; Ghediya M; Jaju J; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(10):e0140375. PubMed ID: 26469691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriologically confirmed pulmonary tuberculosis patients: Loss to follow-up, death and delay before treatment initiation in Bulawayo, Zimbabwe from 2012-2016.
    Mugauri H; Shewade HD; Dlodlo RA; Hove S; Sibanda E
    Int J Infect Dis; 2018 Nov; 76():6-13. PubMed ID: 30030177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time delay and associated mortality from negative smear to positive Xpert MTB/RIF test among TB/HIV patients: a retrospective study.
    Lisboa M; Fronteira I; Colove E; Nhamonga M; Martins MDRO
    BMC Infect Dis; 2019 Jan; 19(1):18. PubMed ID: 30616533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of tuberculosis from smear-negative presumptive TB cases using Xpert MTB/Rif assay: a cross-sectional study from Nepal.
    Khadka P; Thapaliya J; Basnet RB; Ghimire GR; Amatya J; Rijal BP
    BMC Infect Dis; 2019 Dec; 19(1):1090. PubMed ID: 31888522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.